CYP19A1 and polycystic ovary syndrome: Since DHT models do not recapitulate both reproductive and metabolic phenotypes of PCOS [21–25], we developed a pubertal mouse model of PCOS that uses letrozole, a nonsteroidal aromatase inhibitor, to limit the conversion of testosterone to estrogen, leading to increased testosterone and decreased estrogen levels.